2 completed. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow silmitasertib: new trials by email Literature Review of silmitasertib trials Research Report on silmitasertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19 Silmitasertib, SOC - Covid19 | Phase 2 | Completed | Senhwa Biosciences, Inc. | 20 | 2020-11-30 | 2025-01-16 |
| Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma CX-4945, Cisplatin, Gemcitabine - Cholangiocarcinoma | Phase 1 / Phase 2 | Completed | Senhwa Biosciences, Inc. | 127 | 2014-06-01 | 2021-10-22 |
Bile Duct Neoplasms (1) · Biliary Tract Neoplasms (1) · COVID-19 (1) · Cholangiocarcinoma (1)
United States (2) · South Korea (1) · Taiwan (1)
Chris P. Recknor, MD (1) · Mitesh Borad, M.D. (1)